Lahore: BF Biosciences Limited has disclosed a transaction executed by one of its executives, as reported under the Pakistan Stock Exchange (PSX) Regulation 5.6.4. According to the company's announcement, the executive involved is Abdur Rehman, who is currently serving as an executive at the firm.

The transaction took place on October 13, 2025, involving the sale of 50 shares of the company at a rate of 151.43 per share. Despite this transaction, the cumulative number of shares held by Abdur Rehman remains unchanged at zero. The cumulative percentage of shareholding also stands at 0.00%, indicating no change in the executive's overall stake in the company.

According to information available from the Pakistan Stock Exchange (PSX), directors, CEOs, executives, and substantial shareholders, along with their spouses and minors, are required to disclose any transactions involving the company's shares. This information is subsequently presented by the Company Secretary at the Board of Directors' meeting following such transactions.

The company emphasized that any transactions must adhere to a holding period of over six months. If executed within six months, any profits must be deposited with the Securities and Exchange Commission of Pakistan (SECP) as per Section 105 of the Securities Act, 2015. Additionally, no director, CEO, or executive is permitted to deal in the company's shares during the closed period.

BF Biosciences Limited has confirmed that all requisite details have been updated in the UIN Management System, ensuring compliance with regulatory requirements.